Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

SAGE
Sage Therapeutics, Inc
stock NASDAQ

At Close
Jun 17, 2025 3:59:55 PM EDT
9.12USD+0.551%(+0.05)4,129,712
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 17, 2025 9:26:30 AM EDT
9.05USD-0.221%(-0.02)15,553
After-hours
Jun 17, 2025 4:00:30 PM EDT
9.12USD+0.055%(+0.01)2,598
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
05:26AM EST  Needham Maintains Buy on Sage Therapeutics, Raises Price Target to $85   Benzinga
Jan 4, 2022
06:30AM EST  Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022   Business Wire
Dec 27, 2021
09:55AM EST  5 Value Stocks In The Healthcare Sector   Benzinga
Dec 20, 2021
10:37AM EST  Where Sage Therapeutics Stands With Analysts   Benzinga
04:55AM EST  SVB Leerink Maintains Market Perform on Sage Therapeutics, Lowers Price Target to $60   Benzinga
Dec 14, 2021
06:30AM EST  Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health Franchises   Business Wire
Dec 8, 2021
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
07:03AM EST  Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that new analyses from the landscape clinical development program of zuranolone in major depressive disorder or MDD were presented at the American College Of Neuropsychopharmacology Congress.   RTTNews
06:38AM EST  Sage : Data From Clinical Program Further Shows Efficacy & Safety Profile Of Zuranolone For Treatment Of MDD   RTTNews
06:32AM EST  Sage Therapeutics and Biogen Announce New Analyses From LANDSCAPE Clinical Development Program Of Zuranolone In MDD Presented At The American College Of Neuropsychopharmacology Congress   Benzinga
06:30AM EST  Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress   Business Wire
Dec 6, 2021
10:20AM EST  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Dec 1, 2021
08:44AM EST  Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced a positive, one-year Zuranolone 50 mg data in the ongoing open-label SHORELINE study in Patients with major depressive disorder or MDD.   RTTNews
08:41AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case   Benzinga
08:36AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case   Benzinga
06:39AM EST  Sage Therapeutics Announce Positive, One-Year Zuranolone 50 Mg Data On Major Depressive Disorder   RTTNews
06:31AM EST  Sage Therapeutics And Biogen Announce One-Year Zuranolone 50 mg Data In Ongoing Open-Label SHORELINE Study   Benzinga
06:30AM EST  Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD   Business Wire
Nov 29, 2021
06:30AM EST  Sage Therapeutics to Host Sage FutureCast Webcast   Business Wire
Nov 24, 2021
06:30AM EST  Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference   Business Wire
Nov 11, 2021
06:30AM EST  Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference   Business Wire
Nov 3, 2021
12:34PM EDT  What 8 Analyst Ratings Have To Say About Sage Therapeutics   Benzinga
09:21AM EDT  RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $48   Benzinga
09:20AM EDT  Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $80   Benzinga
09:16AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
09:14AM EDT  HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $55   Benzinga
Nov 2, 2021
03:25PM EDT  Sage Therapeutics shares were trading lower after the company reported worse-than-expected Q3 EPS and sales results.   Benzinga
11:52AM EDT  How Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed   Benzinga
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:47AM EDT  Sage Therapeutics Q3 EPS $(2.21) Misses $(1.85) Estimate, Sales $1.44M Miss $1.96M Estimate   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
06:57AM EDT  Sage Therapeutics Q3 Net Loss $130.2 Mln Vs Net Loss $105.7 Mln Last Year   RTTNews
06:30AM EDT  Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress   Business Wire
Nov 1, 2021
11:02AM EDT  Preview: Sage Therapeutics's Earnings   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 20, 2021
04:05PM EDT  Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021   Business Wire
10:34AM EDT  Abbot Labs and Biogen Outshine Novavax in the Health Care Sector   Benzinga
10:18AM EDT  Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $84   Benzinga
07:35AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
05:49AM EDT  Needham Maintains Buy on Sage Therapeutics, Lowers Price Target to $79   Benzinga
Oct 19, 2021
06:59AM EDT  Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company , and Biogen Inc. (BIIB), a biotechnology firm, on Tuesday said they plan to submit a New Drug Application or NDA to the U.S. Food and Drug Administration for Zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022.   RTTNews
06:35AM EDT  Sage Therapeutics, Biogen Plan To Submit NDA For Zuranolone To FDA In H2 Of 2022   RTTNews
06:34AM EDT  Sage Therapeutics and Biogen Announcd Plans to Submit NDA for Zuranolone to FDA in H@ 2022 with Rolling Submission Expected to Start in Early 2022   Benzinga
06:31AM EDT  Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022   Business Wire
Oct 12, 2021
12:27PM EDT  Analyst Ratings For Sage Therapeutics   Benzinga
08:46AM EDT  Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $78   Benzinga
Oct 5, 2021
10:45AM EDT  Rising Oil Prices and Yields Makes Market Navigation More Complex   Benzinga
Oct 4, 2021
08:36AM EDT  Stifel Maintains Buy on Sage Therapeutics, Lowers Price Target to $75   Benzinga
06:39AM EDT  Sage Therapeutics, Biogen Announce New Data From LANDSCAPE And NEST Clinical Development Programs   RTTNews
06:32AM EDT  Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress   Benzinga
Oct 1, 2021
06:35AM EDT  Sage Therapeutics Announces Launch Of SageCitizen - A Social Impact Initiative   RTTNews
06:30AM EDT  Sage Therapeutics Launches SageCitizen Social Impact Initiative   Business Wire
Sep 23, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021   Benzinga
04:47AM EDT  Needham Initiates Coverage On Sage Therapeutics with Buy Rating, Announces Price Target of $84   Benzinga
Sep 21, 2021
06:42AM EDT  Sage Therapeutics Appoints Chris Benecchi As Chief Commercial Officer   Benzinga
Sep 20, 2021
09:45AM EDT  Clinicaltrials.gov Site Shows Sage Therapeutics Study 'Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants' Not Yet Recruiting   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
06:48AM EDT  Biopharmaceutical company Sage Therapeutics, Inc. (SAGE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington's disease (HD).   RTTNews
06:36AM EDT  Sage Therapeutics Gets Fast Track Designation For SAGE-718 For Huntington's Disease   RTTNews
06:31AM EDT  Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington's Disease   Benzinga
Sep 2, 2021
06:30AM EDT  Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference   Business Wire
Aug 23, 2021
10:20AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 16, 2021
10:31AM EDT  Overview Of Value Stocks In The Healthcare Sector   Benzinga
Aug 9, 2021
10:23AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Aug 4, 2021
04:05PM EDT  Sage Therapeutics to Present at Upcoming August Investor Conferences   Business Wire
12:22PM EDT  Where Sage Therapeutics Stands With Analysts   Benzinga
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
07:45AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:08AM EDT  HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $80   Benzinga
Aug 3, 2021
12:46PM EDT  Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval   Benzinga
07:29AM EDT  Sage Therapeutics: Q2 Earnings Insights   Benzinga
06:47AM EDT  Sage Therapeutics Q2 Net Loss $107.2 Mln Vs. Net Loss Of $136.3 Mln Prior Year   RTTNews
06:34AM EDT  Sage Therapeutics Q2 EPS $(1.83) Misses $(1.69) Estimate, Sales $1.64M Miss $2.01M Estimate   Benzinga
06:30AM EDT  Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress   Business Wire
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Jul 29, 2021
12:04PM EDT  Analyst Ratings For Sage Therapeutics   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  Canaccord Genuity Maintains Buy on Sage Therapeutics, Lowers Price Target to $96   Benzinga
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 26, 2021
10:24AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Jul 20, 2021
06:32AM EDT  Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021   Business Wire
Jul 8, 2021
06:30AM EDT  Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit   Business Wire
Jun 24, 2021
06:30AM EDT  Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum   Business Wire
Jun 17, 2021
06:54AM EDT  Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops   Benzinga
Jun 16, 2021
11:50AM EDT  William Blair Downgrades Sage Therapeutics to Market Perform, Announces $62 Price Target   Benzinga
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021   Benzinga
08:17AM EDT  BMO Capital Maintains Market Perform on Sage Therapeutics, Lowers Price Target to $73   Benzinga
08:17AM EDT  Stifel Maintains Buy on Sage Therapeutics, Lowers Price Target to $95   Benzinga
08:03AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
07:50AM EDT  SVB Leerink Maintains Market Perform on Sage Therapeutics, Lowers Price Target to $70   Benzinga
07:23AM EDT  Citigroup Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $68   Benzinga
05:02AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 15, 2021
02:56PM EDT  Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher   Benzinga
12:03PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide   Benzinga
11:30AM EDT  Sage Therapeutics Shares Quiet; Hearing Guggenheim Downgrades From Buy To Neutral   Benzinga
11:25AM EDT  Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug   Benzinga
10:22AM EDT  Shares of biopharmaceutical company Sage Therapeutics, Inc. (SAGE) are down 15 percent on Tuesday's trading. The company, however, cited positive results related to its experimental Phase 3 depression drug Zuranolone.   RTTNews
10:18AM EDT  Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May   Benzinga
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
07:47AM EDT  Sage Therapeutics to Host Conference Call   Business Wire
07:16AM EDT  Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms   Benzinga
06:53AM EDT  Sage, Biogen Announce Positive Pivotal Phase 3 Results For   RTTNews
06:36AM EDT  Sage Therapeutics, Biogen Report Positive Phase 3 Result For Zuranolone In Major Depressive Disorder   RTTNews
06:34AM EDT  Sage Therapeutics And Biogen: WATERFALL Study In Patients With Major Depressive Disorder Met Its Primary Endpoint   RTTNews
06:31AM EDT  Sage Therapeutics And Biogen Announce Pivotal Phase 3 Results For Zuranolone In Major Depressive Disorder; Study Met Primary Endpoint   Benzinga
06:30AM EDT  Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3   GlobeNewswire Inc
06:30AM EDT  Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder   Business Wire
Jun 10, 2021
04:28PM EDT  With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch   Benzinga
May 20, 2021
06:30AM EDT  Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day   Business Wire
May 13, 2021
06:30AM EDT  Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth   Business Wire
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
06:49AM EDT  Sage Therapeutics Q1 EPS $(1.64) Beats $(1.91) Estimate, Sales $1.58M Miss $2.00M Estimate   Benzinga
06:30AM EDT  Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress   Business Wire
Apr 28, 2021
06:30AM EDT  Sage Therapeutics to Present at Upcoming May Investor Conferences   Business Wire
Apr 20, 2021
06:30AM EDT  Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021   Business Wire
Apr 19, 2021
11:11AM EDT  Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $81   Benzinga
10:08AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Apr 12, 2021
02:55PM EDT  Watching Shares Of Sage Therapeutics; Oppenheimer Reiterates Outperform, Sets $102 Price Target   Benzinga
11:46AM EDT  Raymond James On Biogen: Says SAGE-324 Essential Tremor Data Has No Impact On Biogen   Benzinga
11:46AM EDT  Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out   Benzinga
08:23AM EDT  Sage Therapeutics : Phase 2 Study Of SAGE-324 In Essential   RTTNews
07:12AM EDT  Sage Therapeutics and Biogen's Phase 2 Study in Essential Tremor Met its Primary Endpoint   Benzinga
07:04AM EDT  Sage Therapeutics, Biogen: Phase 2 KINETIC Study Of SAGE-324 In Essential Tremor Meets Primary Endpoint   RTTNews
07:00AM EDT  Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint   Business Wire
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 24, 2021
06:30AM EDT  Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day   Business Wire
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
06:40AM EDT  Sage Therapeutics Reports 12-Month Data From 30 mg And 50 mg Cohort Of Zuranolone SHORELINE Study; Says 'more than 70% of patients who received 30 mg and 80% of patients who received 50 mg achieved positive response at Day 15'   Benzinga
06:30AM EDT  Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD   Business Wire
Mar 16, 2021
04:45PM EDT  Sage Therapeutics Reports COO, Mike Cloonan, To Leave Co.; Co. Will Not Seek To Immediately Fill Position   Benzinga
04:45PM EDT  Sage Therapeutics Announces Departure of Chief Operating Officer   Business Wire
Mar 2, 2021
08:16AM EST  Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Raises Price Target to $87   Benzinga
Feb 26, 2021
03:17PM EST  Sage Therapeutics shares were trading lower after Mizuho downgraded the stock from Buy to Neutral and announced a price target of $81 per share.   Benzinga
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 26, 2021   Benzinga
07:33AM EST  Mizuho Downgrades Sage Therapeutics to Neutral, Announces $81 Price Target   Benzinga
Feb 25, 2021
11:51AM EST  Oppenheimer Maintains Outperform on Sage Therapeutics, Raises Price Target to $102   Benzinga
Feb 24, 2021
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
07:09AM EST  Recap: Sage Therapeutics Q4 Earnings   Benzinga
06:35AM EST  Sage Therapeutics Says Recorded $1.1B In Q4 Net Revenue; $1.1B Of Collaboration Revenue From Biogen And $1.7M From Sales Of ZULRESSO   Benzinga
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Jan 22, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 22, 2021   Benzinga
06:10AM EST  BMO Capital Downgrades Sage Therapeutics to Market Perform, Announces $95 Price Target   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 4, 2021
10:04AM EST  Benzinga's Top Upgrades, Downgrades For January 4, 2021   Benzinga
08:43AM EST  RBC Capital Downgrades Sage Therapeutics to Sector Perform, Raises Price Target to $86   Benzinga
07:47AM EST  Guggenheim Upgrades Sage Therapeutics to Buy   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
06:51AM EST  Sage Therapeutics Announces Appointment Of Barry Greene As CEO   Benzinga
Dec 4, 2020
10:06AM EST  Benzinga's Top Upgrades, Downgrades For December 4, 2020   Benzinga
08:00AM EST  10 Biggest Price Target Changes For Friday   Benzinga
05:20AM EST  Mizuho Upgrades Sage Therapeutics to Buy, Raises Price Target to $81   Benzinga
Dec 1, 2020
09:47AM EST  Benzinga's Top Upgrades, Downgrades For December 1, 2020   Benzinga
08:20AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
07:47AM EST  Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $83   Benzinga
06:30AM EST  HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $74   Benzinga
06:23AM EST  Raymond James Downgrades Sage Therapeutics to Market Perform   Benzinga
Nov 27, 2020
08:21AM EST  Benzinga Pro's Top 5 Stocks To Watch For Friday, Nov. 27, 2020: ZM, BIIB, PEIX, PLTR   Benzinga
07:58AM EST  Biogen Inc. (BIIB) and Sage Therapeutics, Inc. (SAGE) said Friday they have entered into a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders, and SAGE-324 for essential tremor and other neurological disorders.   RTTNews
07:37AM EST  Sage Therapeutics Shares To Resume Trade At 8 a.m. EST   Benzinga
07:35AM EST  Biogen And Sage Therapeutics Execute Global Collaboration And License Agreement   RTTNews
07:32AM EST  UPDATE: Sage Therapeutics To Receive $1.525B In Cash, Made Up Of $875M In Upfront Payment, $650M Equity Investment, Potential Milestone, Profit-Sharing, Royalties Payments   Benzinga
07:30AM EST  Biogen, Sage Therapeutics Report Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders   Benzinga
07:30AM EST  Biogen and Sage Therapeutics Announce Global Collaboration to   GlobeNewswire Inc
07:27AM EST  Sage Therapeutics Shares Halted News Pending   Benzinga
Nov 16, 2020
10:21AM EST  B of A Securities Maintains Buy on Sage Therapeutics, Raises Price Target to $95   Benzinga
10:00AM EST  Benzinga's Top Upgrades, Downgrades For November 16, 2020   Benzinga
06:45AM EST  Morgan Stanley Downgrades Sage Therapeutics to Equal-Weight, Announces $85 Price Target   Benzinga
Nov 6, 2020
11:43AM EST  Canaccord Genuity Maintains Buy on Sage Therapeutics, Raises Price Target to $135   Benzinga
07:33AM EST  BMO Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to $89   Benzinga
06:40AM EST  HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Raises Price Target to $81   Benzinga
Nov 5, 2020
08:56AM EST  Sage Therapeutics: Q3 Earnings Insights   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
06:36AM EST  Sage Therapeutics Q3 EPS $(2.03) Beats $(2.39) Estimate   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 15, 2020
06:36AM EDT  Sage Therapeutics Announces Positive Interim, Topline Xuranolone Safety, And Tolerability Data From Open-Label SHORELINE Study In Patients With MDD   Benzinga
Sep 11, 2020
09:38AM EDT  Benzinga's Top Upgrades, Downgrades For September 11, 2020   Benzinga
08:19AM EDT  Wedbush Upgrades Sage Therapeutics to Outperform, Raises Price Target to $65   Benzinga
Sep 10, 2020
06:35AM EDT  Sage Therapeutics Announces Its Ill Host Its 'FutureCast: An R&D Portfolio Review' To Discuss The Co.'s R&D Strategy And Clinical Progress In Its Key Programs   Benzinga
Aug 24, 2020
08:16AM EDT  Morgan Stanley Maintains Overweight on Sage Therapeutics, Raises Price Target to $87   Benzinga
Aug 10, 2020
02:10PM EDT  Raymond James Upgrades Sage Therapeutics to Outperform, Announces $70 Price Target   Benzinga
07:20AM EDT  Recap: Sage Therapeutics Q2 Earnings   Benzinga
06:34AM EDT  Sage Therapeutics Q2 EPS $(2.63) Beats $(2.66) Estimate, Sales $1.09M Beat $890.00K Estimate   Benzinga
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC